{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:31:59Z","timestamp":1786480319973,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH-Cancer support grant","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}]},{"name":"NIH-Cancer support grant","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2026,3]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n Almyloid light chain amyloid patients post autologous stem cell transplantation with higher eGFR was not associated with better progression-free survival but was associated with increased overall survival (OS).<\/jats:p>\n <\/jats:list-item>\n \n Patients with kidney amyloidosis stage 3 at baseline had inferior OS compared with those who had stage 1.<\/jats:p>\n <\/jats:list-item>\n \n OS was better in those who had complete kidney response irrespective of the baseline kidney amyloidosis stage, compared with those without response.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n We investigated how kidney function affected progression-free survival (PFS) and overall survival (OS) after autologous stem cell transplantation (ASCT) in patients with amyloid light chain (AL) amyloidosis.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We performed a retrospective cohort study of 314 patients with AL amyloidosis who underwent ASCT between 2010 and 2020. In addition to the baseline demographics, comorbidities, and kidney amyloidosis stage, eGFR and other laboratory values were collected at day 0, day 100, 6 months, 1 year, 2 years, and 3 years after ASCT. The Cox proportional hazards models were used to estimate hazard ratio (HR) based on landmark analysis for the effects of eGFR and other longitudinal measures on PFS or OS.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Higher eGFR values at all time points after ASCT were not significantly associated with longer PFS but was associated with increased OS. Patients with kidney amyloidosis stage 3 at baseline had inferior OS compared with those who had stage 1 (HR [95% confidence interval] = 9.428 [1.134 to 78.381],\n P<\/jats:italic>\n value = 0.0379). OS was better in those who had complete kidney response irrespective of the baseline kidney amyloidosis stage, compared with those without response (HR [95% confidence interval] = 7.581 [2.042 to 28.149],\n P<\/jats:italic>\n = 0.0025).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This retrospective study shows that kidney function has an effect on survival in patients with AL amyloidosis who undergo ASCT. Both higher eGFR at baseline and complete kidney response after ASCT favor improved survival outcomes.<\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0000001036","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T17:00:39Z","timestamp":1762794039000},"page":"568-582","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The Association of Kidney Function on Survival in Patients with Amyloid Light Chain Amyloidosis after Autologous Stem Cell Transplantation"],"prefix":"10.34067","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2933","authenticated-orcid":false,"given":"Umut","family":"Selamet","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3584-6976","authenticated-orcid":false,"given":"Kole","family":"Joachim","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1779-7007","authenticated-orcid":false,"given":"Heather","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Rondon","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3426-3111","authenticated-orcid":false,"given":"Ruby","family":"Delgado","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valda","family":"Page","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6570-3389","authenticated-orcid":false,"given":"Shveta S.","family":"Motwani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berkay","family":"Dincer","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3673-0104","authenticated-orcid":false,"given":"Giada","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar","family":"Qazilbash","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8168-5811","authenticated-orcid":false,"given":"Naoka","family":"Murakami","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5813-6299","authenticated-orcid":false,"given":"Ala","family":"Abudayyeh","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"3","key":"B1-20260330","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/ndt\/gfm684","article-title":"Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome","volume":"23","author":"Bergesio","year":"2008","journal-title":"Nephrol Dial Transplant."},{"issue":"15","key":"B2-20260330","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood."},{"issue":"7","key":"B3-20260330","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ajh.24738","article-title":"Renal outcomes in patients with AL amyloidosis: prognostic factors, renal response and the impact of therapy","volume":"92","author":"Kastritis","year":"2017","journal-title":"Am J Hematol."},{"issue":"6","key":"B4-20260330","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.2010.30.5235","article-title":"Outcome in renal Al amyloidosis after chemotherapy","volume":"29","author":"Pinney","year":"2011","journal-title":"J Clin Oncol."},{"key":"B5-20260330","doi-asserted-by":"crossref","first-page":"101040","DOI":"10.1016\/j.blre.2023.101040","article-title":"State-of-the-art review on AL amyloidosis in Western countries: epidemiology, health economics, risk assessment and therapeutic management of a rare disease","volume":"59","author":"Sabinot","year":"2023","journal-title":"Blood Rev."},{"issue":"10","key":"B6-20260330","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1182\/blood-2007-07-099481","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation","volume":"110","author":"Sanchorawala","year":"2007","journal-title":"Blood."},{"issue":"11","key":"B7-20260330","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/s41409-019-0524-2","article-title":"Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function","volume":"54","author":"Sidiqi","year":"2019","journal-title":"Bone Marrow Transplant."},{"issue":"9","key":"B8-20260330","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med."},{"issue":"36","key":"B9-20260330","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol."},{"issue":"1","key":"B10-20260330","first-page":"67","article-title":"Systemic light chain amyloidosis, version 2.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Canc Netw."},{"issue":"4","key":"B11-20260330","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol."},{"issue":"10","key":"B12-20260330","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia."},{"issue":"3","key":"B14-20260330","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep."},{"issue":"2","key":"B15-20260330","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Ser B: Stat Methodol."},{"issue":"24","key":"B16-20260330","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2797::AID-SIM290>3.0.CO;2-V","article-title":"On the relationship between response to treatment and survival time","volume":"15","author":"Buyse","year":"1996","journal-title":"Stat Med."},{"issue":"9 Pt 1","key":"B17-20260330","doi-asserted-by":"crossref","first-page":"746","DOI":"10.7326\/0003-4819-134-9_Part_1-200105010-00011","article-title":"Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease","volume":"134","author":"Dember","year":"2001","journal-title":"Ann Intern Med."},{"issue":"7","key":"B18-20260330","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.bmt.1703200","article-title":"An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis","volume":"28","author":"Sanchorawala","year":"2001","journal-title":"Bone Marrow Transplant."},{"issue":"10","key":"B19-20260330","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","article-title":"Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients","volume":"91","author":"Comenzo","year":"1998","journal-title":"Blood."},{"issue":"8","key":"B20-20260330","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.bbmt.2019.04.024","article-title":"Outcomes of patients with light chain amyloidosis who had autologous stem cell transplantation with 3 or more organs involved","volume":"25","author":"Al Saleh","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"B21-20260330","first-page":"55","article-title":"Reconstructive surgery in arteriosclerotic occlusions of the abdominal aorta and iliac arteries","volume":"28","author":"Antushev","year":"1988","journal-title":"Kardiologiia."},{"issue":"10","key":"B22-20260330","doi-asserted-by":"crossref","first-page":"E458","DOI":"10.1002\/ajh.24464","article-title":"Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation","volume":"91","author":"Havasi","year":"2016","journal-title":"Am J Hematol."},{"issue":"10","key":"B23-20260330","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1001\/jamaoncol.2024.2629","article-title":"Graded organ response and progression criteria for kidney immunoglobulin light chain amyloidosis","volume":"10","author":"Muchtar","year":"2024","journal-title":"JAMA Oncol."},{"issue":"7","key":"B24-20260330","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00277-008-0652-z","article-title":"Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience","volume":"88","author":"Frossard","year":"2009","journal-title":"Ann Hematol."},{"issue":"7","key":"B25-20260330","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0002-9343(02)01208-1","article-title":"Stem cell transplantation for the management of primary systemic amyloidosis","volume":"113","author":"Gertz","year":"2002","journal-title":"Am J Med."},{"issue":"2","key":"B26-20260330","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/j.ajkd.2005.05.010","article-title":"Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis","volume":"46","author":"Leung","year":"2005","journal-title":"Am J Kidney Dis."},{"issue":"7","key":"B27-20260330","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/ndt\/gfab189","article-title":"Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis","volume":"37","author":"Nader","year":"2022","journal-title":"Nephrol Dial Transplant."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:03:35Z","timestamp":1786478615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001036"}},"subtitle":["A Multicenter Study"],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000001036","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"2025-07-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}